Medline International to acquire medical products supplier ASID BONZ

Martin Lehner, Chief Executive Officer of Medi-Globe Group

Medline International B.V., a manufacturer of healthcare supplies in Europe, and Medi-Globe Group, headquartered in Germany, announced that Medline has entered into a definitive agreement to acquire 100% of shares of ASID BONZ GmbH from Medi-Globe Group.

What does this deal mean to Medline International?

ASID BONZ is a leading supplier to hospitals in Germany, offering high-quality surgery, anesthesia, ward-supply and urology products. ASID BONZ was founded in 1811 and is known worldwide for the development of the first anesthetic ether. In 2021, ASID BONZ recorded over 30million Euros in revenues and served over 1100 hospitals in Germany.

With similar business models and reputations for outstanding customer service, the two companies have an excellent strategic fit. Medline will make the ASID BONZ brand available outside of Germany to its broad European clients. Within Germany, the ASID BONZ sales force will have access to Medline products to strengthen their partnership with customers.

“We are excited to increase our product offering and work with this organization with a renowned customer focus,” said Tripp Amdur, Medline Europe Group President.

“Medline is a relatively new player in urology and anesthesia. This acquisition grows our presence in these areas of the hospital. ASID BONZ’s employees, products and service have a long-standing and trusted reputation and this combination will enable us to better meet the needs of our healthcare customers and become a more valued partner,” he added.

What does the deal mean to Medi-Globe Group?

Martin Lehner, CEO of Medi-Globe Group asaid: “ASID BONZ is known for its commitment to its clients, providing high-quality products used to treat patients every day. We are sure that under the ownership of Medline, ASID BONZ will provide substantial avenues of growth.”

“The sale increases Medi-Globe’s focus on the core business, the development and marketing of single-use products for minimally invasive diagnostic and therapeutic procedures.”

We anticipate the investment will be completed in May 2022 once merger control approval has been obtained and other closing conditions have been fulfilled.